GBtherapeutics Ltd. has amassed a large library of nitric oxide mimetics that selectively target brain tissue. The Canadian start-up believes that these compounds, which operate through multiple mechanisms not fully characterized, present new ways to combat age-related declines in cognition and memory.

Molecular Mining Corp. bills itself as an expert in KDD or "knowledge discovery and data mining." The company's first offering will likely address gene expressoin data. Scientists believe that proper statistical analysis of the data should reveal genes that are co-regulated, and possibly even entire regulatory pathways.

Vaxis Therapeutics enters a market made popular by {Viagra}: it is developing both oral and local therapies for male and female sexual dysfunction.

Queen's University has one of the most productive technology transfer operations in North America. In a 1998 survey published by AUTM, Queen's ranks fourth in a list of 50 North American research organizations. With a research budget of $46 million, Queen's technology transfer office, PARTEQ, has spun-off 19 companies, 8 of them in life sciences, and receives about $1.45 million in total revenues annually.